Caris Life Sciences, Inc.
CAI- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- SEC CIK
- 0002019410
In the last 90 days, Caris Life Sciences, Inc. insiders filed 1 open-market purchase and 3 sales; 247 institutions reported holding it in 13F filings for Q2 2026, worth $2.75B in total; superinvestors Coatue Management and Duquesne Family Office hold it.
Superinvestors holding CAI, Q2 2026
2 superinvestors report holding Caris Life Sciences, Inc. on Form 13F, worth $208.8M in total. Weight is Caris Life Sciences, Inc.'s share of each 13F portfolio; actions compare shares with Q1 2026.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| Coatue ManagementPhilippe Laffont | 0.4% | 9,819,992 | $175.0M | Unchanged |
| Duquesne Family OfficeStanley Druckenmiller | 0.8% | 1,894,450 | $33.8M | Unchanged |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of CAI each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q1 2026
2 superinvestors holding at quarter end
- New
- Duquesne Family Office
- Sold out
- ARK Invest
Q4 2025
2 superinvestors holding at quarter end
- Added
- ARK Invest (+66.6%)
- Reduced
- Coatue Management (−3.2%)
- Sold out
- Soros Fund Management
Q3 2025
3 superinvestors holding at quarter end
- Added
- ARK Invest (+421.5%), Soros Fund Management (+11.3%)
Q2 2025
3 superinvestors holding at quarter end